【摘要】 目的 探讨肌内注射齐拉西酮注射液治疗精神分裂症患者急性激越症状的疗效和安全性。方法 将80例伴急性激越症状的精神分裂症患者随机分为两组,实验组肌内注射齐拉西酮注射液治疗,对照组肌内注射氟哌啶醇注射液治疗,观察3 d。于治疗前后采用阳性与阴性症状量表总分及兴奋因子分评定临床疗效,副反应量表评定不良反应。结果 治疗第1 d起两组阳性与阴性症状量表总分及兴奋因子评分均较治疗前显著下降(P<0.01),治疗各时点两组评分比较差异均无显著性(P>0.05);治疗第3 d后实验组急性激越症状显效率67.5%、总有效率92.5%,对照组分别为72.5%、95.0%,两组比较差异无显著性(X~2=0.24、0.21,P>0.05)。两组不良反应程度较轻微,但研究组不良反应发生率显著低于对照组(X~2=4.11,P<0.05)。结论 肌内注射齐拉西酮注射液能够快速有效控制精神分裂症急性激越症状,疗效与氟哌啶醇相当,但安全性更高,有利于患者的连续性治疗。更多还原

【Abstract】 Objective To explore the efficacy and safety of ziprasidone intramuscular injection for acutely agitated symptoms of schizophrenia.Methods Eighty schizophrenics with acutely agitated symptoms were randomly divided into two groups,experimental group was treated with intramuscular ziprasidone and control group with haloperidol for 3 days.Before and after treatment efficacies were assessed with the total and excitatory factor score of the Positive and Negative Syndrome Scale（PANSS）and adverse reactions with the Treatment Emergent Symptom Scale（TESS）.Results Since the 1^stday of treatment the total and excitatory factor score of the PANSS of both groups lowered more significantly compared with pretreatment（P<0.01）,there were no significant group differences in each time-point score（P>0.05）;after the 3^rd day treatment obvious and total effective rate were respectively 67.5%and 92.5%in experimental and 72.5%and 95.0% in control group,which showed no significant group differences（x²=0.24,0.21;P>0.05）.Adverse reactions of both groups were mild,but their incidence was significantly lower in research than in control group（X²=4.11,P<0.05）.Conclusion Intramuscular ziprasidone could quickly and effectively control acutely agitated symptoms of schizophrenia,its efficacy is equivalent to haloperidol,but its safety higher,and it beneficial to patients’ continuous treatment.更多还原